4NI Stock Chart & Stats
€1.04
€0.00(0.00%)
At close: 4:00 PM EDT
€1.04
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.99 - €2.18
Previous CloseN/A
Volume0.00
Average Volume (3M)303.00
Market Cap
€59.70M
Enterprise Value€55.32
Total Cash (Recent Filing)€55.84M
Total Debt (Recent Filing)€56.21M
Price to Earnings (P/E)―
Beta1.23
Next Earnings
Nov 04, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding42,237,200
10 Day Avg. Volume80
30 Day Avg. Volume303
Financial Highlights & Ratios
PEG Ratio0.22
Price to Book (P/B)1.66
Price to Sales (P/S)0.99
P/FCF Ratio-2.73
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.04Price Target Upside191.89% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-1
Revenue Forecast (FY)€79.25M
Bulls Say, Bears Say
Bulls Say
High Gross MarginSustained ~75%+ gross margins indicate strong unit economics for the Zephyr system and consumables. High product margins provide structural leverage: each incremental procedure contributes meaningfully to covering fixed costs and shortening the path to operating break‑even as volumes recover, supporting durable profitability potential.
Expense Reduction & Profitability ProgressMeaningful, repeatable expense cuts and a nearly 40% reduction in adjusted EBITDA loss reflect improved cost discipline and execution. Lower structural operating cost run‑rate reduces required revenue to reach break‑even, extends runway, and makes future margin expansion easier as sales normalize.
Improved Liquidity & Financing FlexibilityStronger liquidity and an extended credit maturity materially reduce near‑term refinancing risk and provide time to execute commercial plans and complete CONVERT II enrollment. Contingent $20M access further mitigates funding pressure, improving the company's ability to fund R&D and commercialization without immediate dilution.
Bears Say
Persistent Cash BurnOngoing negative operating and free cash flow demonstrates the business still consumes significant cash to run operations and grow adoption. Because losses largely translate into cash burn, the company remains dependent on external financing or improved operating performance to avoid dilution or constrained investment in commercial scale.
Revenue Decline & China DisruptionNear‑term top‑line deterioration driven by a China shipment suspension highlights reliance on regulatory and distributor stability for growth. Delayed China revenues and the multi‑quarter ramp for new sales hires mean structural growth may be postponed, increasing execution risk for achieving sustained global revenue expansion.
Rising Leverage & Shrinking EquityA materially higher leverage ratio and diminished equity cushion reduce financial flexibility and heighten refinancing or covenant risk if losses persist. Rising leverage narrows options for funding growth and increases the likelihood of dilutive or costly capital raises absent sustained improvement in profitability or cash generation.
Pulmonx News
4NI FAQ
What was Pulmonx’s price range in the past 12 months?
Pulmonx lowest stock price was €0.99 and its highest was €2.18 in the past 12 months.
What is Pulmonx’s market cap?
Pulmonx’s market cap is €59.70M.
When is Pulmonx’s upcoming earnings report date?
Pulmonx’s upcoming earnings report date is Nov 04, 2026 which is in 89 days.
How were Pulmonx’s earnings last quarter?
Pulmonx released its earnings results on Jul 29, 2026. The company reported -€0.208 earnings per share for the quarter, beating the consensus estimate of -€0.243 by €0.035.
Is Pulmonx overvalued?
According to Wall Street analysts Pulmonx’s price is currently Undervalued.
Does Pulmonx pay dividends?
Pulmonx does not currently pay dividends.
What is Pulmonx’s EPS estimate?
Pulmonx’s EPS estimate is -0.22.
How many shares outstanding does Pulmonx have?
Pulmonx has 42,237,200 shares outstanding.
What happened to Pulmonx’s price movement after its last earnings report?
Pulmonx reported an EPS of -€0.208 in its last earnings report, beating expectations of -€0.243. Following the earnings report the stock price went up 5.607%.
Which hedge fund is a major shareholder of Pulmonx?
Currently, no hedge funds are holding shares in DE:4NI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pulmonx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€3.04 (191.89% Upside)
€3.04 (191.89% Upside)
Blogger Sentiment
Bearish
DE:4NI Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €124.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-22.05%
Trailing 12-Months
Company Description
Pulmonx
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically engineered to treat bronchoscopic hyperinflation in adults afflicted with severe emphysema. Complementing its therapeutic solutions, the company also provides the Chartis Pulmonary Assessment System. This system features a specialized balloon catheter and console, fitted with flow and pressure sensors, which is instrumental in evaluating the presence of collateral ventilation in patients. Additionally, Pulmonx offers the StratX Lung Analysis Platform, a cloud-based service that conducts quantitative computed tomography (CT) analysis. This platform delivers vital data concerning emphysema destruction, fissure completeness, and lobar volume, thereby aiding clinicians in accurately identifying the most suitable target lobes for treatment with Zephyr Valves. Pulmonx serves emphysema patients across a broad international footprint, encompassing the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. The company, which changed its name from Pulmonx to Pulmonx Corporation in December 2013, was originally incorporated in 1995 and maintains its corporate headquarters in Redwood City, California.
4NI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a cautiously optimistic picture: multiple operational and financial improvements (notably a nearly 40% reduction in adjusted EBITDA loss, 16% YoY reduction in operating expenses, gross margin expansion, China registration renewal, filled U.S. leadership roles, and reiterated full-year guidance) signal meaningful progress on execution and financial leverage. Near-term challenges remain, including an overall revenue decline driven by the China shipment suspension, ongoing quarterly losses and cash burn, typical seasonality (Q3), and the multi-quarter ramp required for new sales hires and clinical enrollment timelines. On balance, the positive operational and balance-sheet developments outweigh the near-term headwinds, but material execution is still required to convert momentum into sustained revenue growth.View all DE:4NI earnings summaries4NI Stock 12 Month Forecast
Average Price Target
€3.04
▲(191.89% Upside)
Technical Analysis
Apyx Medical
―
Xtant Medical Holdings
―
Sensus Healthcare
―
TELA Bio
―
Icecure Medical
―